Regend Therapeutics
Suzhou
About Regend Therapeutics
Regend Therapeutics focuses on the human organ regenerative medicine business and is a global leader in this field. Its core product REGEND001 cell preparation has been accepted by the State Food and Drug Administration and is the world's first autologous stem cell product for respiratory diseases. The company is also the first company in China to be registered by the National Health and Health Commission and the Food and Drug Administration, and is allowed to conduct clinical research on stem cells (Registration No.: CMR-20161214-1002). It is also the first batch of key research and development programs of the Ministry of Science and Technology. And companies that transform research topics. At present, the company has passed ISO9001:2008 quality management system certification, and the stem cell preparation has passed the China Metrology Accreditation (CMA), China Conformity Assessment Committee (CNAS) and IAF International Mutual Recognition. All clinical programs of Jimmy Suisheng are strictly in accordance with the regulations of the National Health Care Commission and the Food and Drug Administration, and are registered with the National Trial Global Database of the National Institutes of Health.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 101 – 250
- Estimated revenue: $10K – $50K
- Total funding: $66.5M
- Funding stage: Late Stage Venture
- Last round: Series C (Feb 2026)
- Website: regend.cn
- Phone: 0512-87899182
Industries & Categories
Biotechnology, Health Care, Therapeutics
Canonical: https://fsome.com/organization/regend-therapeutics-40778 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.